相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I
William T. Lowrance et al.
JOURNAL OF UROLOGY (2021)
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II
William T. Lowrance et al.
JOURNAL OF UROLOGY (2021)
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial
Linda G. W. Kerkmeijer et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
Vedang Murthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results
Peter J. Hoskin et al.
RADIOTHERAPY AND ONCOLOGY (2021)
ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist
Anthony L. Zietman
PRACTICAL RADIATION ONCOLOGY (2021)
Progress in Low Dose Rate Brachytherapy for Prostate Cancer
Patrick W. McLaughlin et al.
SEMINARS IN RADIATION ONCOLOGY (2020)
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer The ORIOLE Phase 2 Randomized Clinical Trial
Ryan Phillips et al.
JAMA ONCOLOGY (2020)
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
Christopher C. Parker et al.
LANCET (2020)
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial
Andrew Kneebone et al.
LANCET ONCOLOGY (2020)
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial
Paul Sargos et al.
LANCET ONCOLOGY (2020)
Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
Liselotte M. S. Boeve et al.
EUROPEAN UROLOGY (2019)
Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer
Zaid A. Siddiqui et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial
Seth A. Rosenthal et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma et al.
LANCET (2019)
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
Anders Widmark et al.
LANCET (2019)
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
Douglas H. Brand et al.
LANCET ONCOLOGY (2019)
Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial
Abdenour Nabid et al.
EUROPEAN UROLOGY (2018)
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Piet Ost et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer The NRG Oncology RTOG 0126 Randomized Clinical Trial
Jeff M. Michalski et al.
JAMA ONCOLOGY (2018)
Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer
Karen E. Hoffman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial
A. Pollack et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Christopher C. Parker et al.
LANCET (2018)
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
W. James Morris et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial
Daniel A. Hamstra et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer
Charles N. Catton et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
W. U. Shipley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer
Peter Hoskin et al.
RADIOTHERAPY AND ONCOLOGY (2017)
Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial
T. Major et al.
BRACHYTHERAPY (2017)
High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results
Henrik Hauswald et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer
Maha Saada Jawad et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study
Pascal Pommier et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
W. Robert Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial
Luca Incrocci et al.
LANCET ONCOLOGY (2016)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David Dearnaley et al.
LANCET ONCOLOGY (2016)
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial
Christian Carrie et al.
LANCET ONCOLOGY (2016)
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
F. C. Hamdy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy
Neil Mariados et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer
Jeffrey J. Tosoian et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
Laurence Klotz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial
Karim Fizazi et al.
LANCET ONCOLOGY (2015)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Impact of Adjuvant Radiotherapy on Survival of Patients With Node-Positive Prostate Cancer
Firas Abdollah et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A New Risk Classification System for Therapeutic Decision Making with Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation Therapy
Zachary S. Zumsteg et al.
EUROPEAN UROLOGY (2013)
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
Michel Bolla et al.
LANCET (2012)
High-Dose-Rate Prostate Brachytherapy An Excellent Accelerated-Hypofractionated Treatment for Favorable Prostate Cancer
Alvaro A. Martinez et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95
Thomas Wiegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial
Ian M. Thompson et al.
JOURNAL OF UROLOGY (2009)
An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions
Colleen A. Lawton et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy
Edward M. Messing et al.
LANCET ONCOLOGY (2006)
分享论文
